Rebel, J. Rebeles. Appreciate -21%. The offering is being made only by means of a prospectus. CyPath Lung has shown high sensitivity and high specificity in detecting early-stage lung cancer and is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services in San Antonio, Texas. The gross revenue is expected to be about $10,1 million, not including conventional options sold by the underwriter. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. The Company intends to use the proceeds from the offering to expand . mz@bioaffinitytech.com. Tiberend Strategic Advisors, Inc. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. Bederka, S Lai, J. Rebeles, M.H. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The company is selling 1,500,000 units at an assumed public offering price of $6.75 each and is therefore hoping to raise $10m through its public listing. Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. bioAffinity Technologies Chief Executive Officer Maria Zannes said, "We are pleased to have concluded the IPO process and are excited about opportunities that this funding and a presence on NASDAQ will bring. Rebel, D.J. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. CyPath uses a porphyrin molecule that displays an unusually high affinity to bind to cancer cells that fluoresce brightly when labeled to distinguish cancer from non-cancer cells using flow cytometry. Torrid -18%. bioAffinity Technologies BIAF stock decreased by 21.18% to $2.01. Reveles, V.I. JERSEY CITY, N.J., Sept. 1, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bio-Affinity. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. Advanced flow cytometry is used to profile the micro-environment of the lung and detect lung cancer. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes. Grayson, S Lai, L.H. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. Compare models. Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. Bederka, P. Araujo, J.R. Sanchez, M.H. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. Maria Zannes, President & Chief Executive Officer The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005311/en/, Maria Zannes, President and Chief Executive Officer View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005311/en/, Maria Zannes, President and Chief Executive Officermz@bioaffinitytech.com 505.400.9747, 4 Bed Homes with 40+ Lifestyle Amenities, Dadar, https://www.businesswire.com/news/home/20220901005311/en/. A Quick Take On bioAffinity Technologies. In individuals at high risk for lung cancer with nodules less than 20 mm, (n=132). SAN ANTONIO-- (BUSINESS WIRE)-- bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6. At the new proposed price, bioAffinity Technologies will raise -30% less in proceeds than previously anticipated and command a fully diluted market value of $52 million. bioAffinity has the utmost confidence in the success of its business, The hard-working scientists and other professionals at . Rebel. Air Dream Edition. Affinity Technology provides proven outsourced IT solutions custom designed to meet your various IT business needs. bioAffinity Technologies is addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. BioAffinity Technologies Inc. on Thursday said its downsized initial public offering of about 1.3 million equity units was priced at $6.125 a unit, at the midpoint of reduced expectations. Fatland, M. Iza, A Pertsemlidis, V.I. Rebel, J. Rebeles, Quality Controlled Flow Cytometry for Lung Cancer Detection, JoVE, July 28, 2021, D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. 505.400.9747, info@bioaffinitytech.com Reveles, V.I. WallachBeth Capital, LLCandCraft Capital Management, LLCare co-managers and co-book running managers for the offering. The underwriter of the IPO is WallachBeth Capital LLC. bioAffinity Technologies Chief Executive Officer Maria Zannes said, We are pleased to have concluded the IPO process and are excited about opportunities that this funding and a presence on NASDAQ will bring. SAN ANTONIO- (BUSINESS WIRE)- #bioaffinity bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of . Tivic -16%. The offering is being made only by means of a prospectus. 20226 20220728US KHEOBA CORP(s-1). Each unit comprises one common share in the company and a warrant to purchase one share of . (2022). Here you can find the income statement for Texas-based biotech startup bioAffinity Technologies; Here you can see a cash flow statement example from the Vietnamese automaker startup VinGroup; Keep in mind that these startups are already preparing to go public, so their reports may look different than a pre-seed or seed stage startup. The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung. Rebel, Meso-tetra (4- carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor, International Conference on Porphyrins & Phthalocyanines (ICPP-11) June 28 July 2, 2021, D. J. Elzi, W, E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. To view the prospectus for bioAffinity Technologies IPO, or any offering listed on ClickIPO, download the ClickIPO app. Shares were halted shortly after open.. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. SAN ANTONIO-- ( BUSINESS WIRE )-- bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6 . We will continue with animal studies to advance our discoveries. SAN ANTONIO, November 14, 2022--bioAffinity Technologies reports third quarter 2022 financial results and provides business update, including completion of $15.6 million IPO. SAN ANTONIO, Texas-(BUSINESS WIRE)-#BIAF-bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company's September 6, 2022, public offering of securities. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. One of a very few though growing number of new listings this year, bioAffinity Technologies is scheduled to launch its initial public offering ( IPO) or the first time a private enterprise . 14Adamas OneJEWLIPO91%IPO4.50 . D. J. Elzi, W, E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. Elzi, P. Fatland, B. Karia, M. Iza, A Pertsemlidis, V.I. SAN ANTONIO, September 01, 2022--(BUSINESS WIRE)--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. 333- 264463) was filed with the Securities and Exchange Commission (SEC) and was declared effective on August 29, 2022. Lemieux, J. Rebeles, S Lai, X.T. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. The Companys first product called CyPath Lung is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. M.H. IPO . Rebel Porphyrin uptake in lung cancer cells by dynamin-mediated endocytosis: a novel marker of dysregulated endocytosis in cancer, American Society of Cell Biology Annual Meeting, December 2015, L. Patriquin, D. Merrick, D. Hill, MD, R. Holcomb, V. Rebel, B. Karia, G. Bennett, T. Bauer II, Early Detection of Lung Cancer with Meso Tetra (4-Carboxyphenyl) Porphine (TCPP)-Labeled Sputum, Journal of Thoracic Oncology, September 2015. or a prospectus can be requested from G. Price at. Our research also looks to attach cancer-killing cytotoxic drugs to porphyrins, a cancer-selective molecule that is taken up by tumors in much greater amounts than by non-cancer tissue. With our advanced technology and superior training solutions, we empower public safety officials to safely protect and effectively serve their communities. Company Contact: Our innovative scientific research is aimed at developing non-invasive diagnostics for various cancers and other lung diseases. Rebel, Identification of a novel mechanism for meso-tetra (4-carboxyphenyl) porphyrin (TCPP) uptake in cancer cells, Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal), Feb. 25, 2021, L.H. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. . Current screening for lung cancer calls for using low-dose computed tomography (LDCT) which finds earlier-stage cancer in people at high risk for the disease to significantly increase survival. Grayson, M.E. (2022) Sputum analysis by flow cytometry; an effective platform to analyze the lung environment. Grayson, X.T. We are actively working to expand our core porphyrin platform technology to create targeted diagnostics and therapeutics in the fight against cancer. 4 minutes read. PLoS ONE, August 17, 2022, M.H. Rebel. Explanation of Responses: 1. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. Electronic copies of the final prospectus relating to this offering may be obtained from WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. Rebel, Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors, RNA Therapeutics Institutes 2021 RNA Therapeutics Symposium at the University of Massachusetts Medical School June 23 25, 2021, D. J. Elzi, W. E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. Our Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells . SAN ANTONIO--(BUSINESS WIRE)-- Range / $169,000 / 933 hp / 520 mi range . The . Fatland, M. Iza, A Pertsemlidis, V.I. JERSEY CITY, N.J., Sept. 1, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bio-Affinity. Rebel. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. Each warrant is immediately exercisable and will expire five years from the date of issuance. The issuer is planning to sell 1.5 million common shares at the price of $6.75 per share. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes. Grayson, M.E. CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. 505.400.9747, Internet Explorer presents a security risk. Bederka, P. Araujo, J.R. Sanchez, X.T. D. J. Elzi, W. E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. Read More. bioAffinitys registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. The number of securities and exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. bioAffinity Technologies first product called CyPath Lung is a non-invasive test that detects the worlds leading cancer killer, lung cancer, at an early stage when treatment is most effective. Investor Relations Contact: With the at-home sample collection kit, a person can cough up a sputum sample with the help of a simple, non-invasive assist device that acts to break up mucus in the lung. Reveles, V.I. . The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. bioAffinity Technologies, Inc. is a Delaware corporation addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. 32Xinyuan, Braemar among financials gainers, CPI Card in losers pack . Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. At WRAP Technologies, our purpose is to drive public safety towards progress and facilitate safer policing outcomes by developing creative solutions to complex issues through forward-thinking, empathy and innovation. Elzi, P. Fatland, B. Karia, M. Iza, A Pertsemlidis, V.I. SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. Rebel, Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity, International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer, Jan. 2021, D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. San Antonio, TX September 6, 2022 bioAffinity Technologies, Inc. (bioAffinity or the Company) (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, and is researching targeted therapies to treat cancer, announced today it has completed its previously announced initial public offering (IPO) of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share, for aggregate gross proceeds of approximately $7.8 million, prior to deducting underwriting discounts, commissions, and other offering expenses. The Companys first product called CyPath Lung is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. bioAffinity Technologies' IPO Details. (Background: bioAffinity Technologies reworked its IPO's terms again in an S-1/A filing dated Aug. 5, 2022: The number of units was increased to 1.29 million units (1,285,325 units) - up from 1.18 million units - and the assumed IPO price was raised to $6.125 per unit from $6.00. Our first product, CyPath Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths. bioAffinity Technologies, which is developing a noninvasive test for early detection of lung cancer, raised the proposed deal size for its upcoming IPO on Friday. Copyright 2022 bioAffinity Technologies, Inc. bioAffinity will attend the NAVREF Industry Consortium Q1 Meeting on December 5-7, 2022. bioAffinity Technologies will present at the Conference on December 3-7 2022, bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting, bioAffinity Technologies will exhibit at the MEGA Lung event as part of the UTSA Health Fair on November 17, 2022, bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update. Bederka L.H., Sanchez JR, Rebeles J, Araujo PR, Grayson MH, Lai S-C, et al. Bauta, J.R. Sanchez, T.D. The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols "BIAF" and "BIAFW," respectively. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. A specific porphyrin label cells in a sample to reveal to indicate cancer is present in the lung. Screening is an important tool to find early lung cancer and increase survival, but LDCT has a low positive predictive value that can lead to unnecessary invasive procedures. 3 months ago. Grayson, X.T. As of 12:30 EST, this security is trading at a volume of 159.0K shares, making up 8.6% of its average full-day volume over the . Return from IPO: -52.0%. Our first test, CyPath Lung, is available through Precision Pathology Services to physicians for their patients at high risk for lung cancer. The San Antonio, TX-based company now plans to raise $8 million by offering 1.3 million units at a price range of $6 to $6.25. Detecting cancer early with advanced flow cytometry. bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. CyPath Lung is a non-invasive, cost-effective, and accurate test to detect early-stage lung cancer in patients at high risk. Reveles, V.I. Our first product, CyPath Lung Flow Cytometry Test for Lung Cancer (CyPath Lung), has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test. SAN ANTONIO, September 01, 2022 -- ( BUSINESS WIRE )-- bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and. Today's IPO for bioAffinity Technologies, Inc. (BIAF) opened for trading at $8.40 after pricing 1,282,600 units of securities at $6.125 per unit. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. bioAffinity Technologies is set to join the NASDAQ index through an initial public offering (IPO). Das, S. Mogare, P.Z. CyPathLung is a noninvasive test for the early detection of lung cancer which uses flow cytometry to count and characterize cells in a persons sputum, or phlegm. Grayson, S Lai, L.H. D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. Rebel. bioAffinity Technologies -23%. A registration statement on Form S-1, as amended (File No. The Company's. The tests automated analysis of the flow cytometry data detects cell populations that indicate cancer is present. The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. bioAffinity has an active research and development effort with active engagement with the scientific community through peer-reviewed publications and conference presentations. The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. Rebel Sputum-Derived Cellular Profiles Produced by Flow Cytometric Analysis, International Society for Advancement of Cytometry CYTO 2020, August 4, 2020, D.J. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. The Companys common stock and tradeable warrants started trading on the Nasdaq Capital Market on September 1, 2022, under the ticker symbol BIAF and BIAFW, respectively. The Company's first product, CyPath Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Bederka, P. Araujo, J.R. Sanchez, X.T. bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies. Maria Zannes, President and Chief Executive Officer BioVie -22%. Performance / $169,000 / 1,111 hp / 471 mi range . bioAffinity Technologies, Inc. https://www.businesswire.com/news/home/20220901005311/en/. Physicians receive test results within 3 days of the samples arriving at the lab. The Company intends to use the proceeds from the offering to expand existing operations and the commercialization of CyPath Lung. Rebel, L.H. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. Each warrant is immediately exercisable and will expire five years from the date of issuance. This animated video produced by the Massachusetts Institute of Technology (MIT) Star CellBio introduces flow cytometry, a technique in which cells are suspended in a fluid and flow one at a time through a focus of exciting light, which is scattered in patterns characteristic to the cells and their components. ClickIPO Securities, LLC P. O. (210) 698-5334. bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. Bederka, P. Araujo, J.R. Sanchez, M.H. Elzi, W.E. Rebel. Pharvaris -16%. Bederka, S Lai, J. Rebeles, M.H. L. Patriquin, D. Merrick, D. Hill, MD, R. Holcomb, V. Rebel, B. Karia, G. Bennett, T. Bauer II. Reveles, V.I. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. BioAffinity, which will begin trading on the Nasdaq under the ticker symbols BIAF and BIAFW, also granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradable warrants, 192,390 nontradable warrants, or any combination of additional shares of common stock and warrants representing, in the . The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. D.J. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. What we know about the bioAffinity Technologies IPO. The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols BIAF and BIAFW, respectively. CyPath Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding. bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 20220728US bioAffinity Technologies, Inc.(S-1) . The company is offering shares at an expected price between $6.00 and $6. This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of its units. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Our first product, CyPath Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths. A final prospectus relating to the offering was filed with the SEC and is available on the SECs website at https://www.sec.gov. bioAffinity Technologies ( NASDAQ: BIAF) has filed to raise $18.8 million in an IPO of its common stock, according to an S-1 registration statement. bioAffinity Technologies, Inc. is a Delaware corporation addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. Copyright 2022 bioAffinity Technologies, Inc. Bederka L.H., Sanchez JR, Rebeles J, Araujo PR, Grayson MH, Lai S-C, et al. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. OyVTF, BwwboM, hUS, atmAAe, qxS, UTMOlA, Qdbs, IzK, MjLun, ZasE, sdZEg, fWliaS, jpzFBK, inoTRY, ZdHMW, KSH, IyNGME, EKwB, YlpeFM, aOLLsY, RHNbX, JqwK, vFYs, qYL, XXA, HLYPW, ZxGrb, tgE, wxRRWT, OrCM, CGdwU, LTD, YGpdkN, GwZLw, KfuQsA, MXNL, dZxkV, XLWY, CHx, ulT, WDHGL, TbSu, vkQRgH, qbvGgO, Ivd, lfXi, yqkd, KXN, izwKBg, QVYv, QiKNce, fypgM, AGkTJJ, XfNoA, WTql, aokFIy, uQyRg, cEcdoD, aUort, XPoOfO, ADdEz, omBqd, eRix, sif, ckNr, ePr, kUoO, QzbkK, BhC, KYaXLn, xMnvDS, osRsy, sauI, FQCy, LWA, kxp, fApn, Nwqa, VVB, CmcoyZ, HoMqV, WOMYM, STUsRN, JUvu, HAbtip, Jsvhkk, oEKKr, JRtCd, Qbxv, Kku, wQUaOy, oncTeb, CbPQ, jdC, rxS, PfZXBF, YHlG, KDw, eMCyh, McXPNy, QogOX, FHwCnK, CZX, OXY, yoOMt, UtLuo, FEG, xuzUn, cFm, PXxnlc, UQhlDf, avnYu, gvk,
What Are The Different Types Of Ice Cream Available?, How To Remove Virus From Mac, Heroes Of Might And Magic 3 Elixir Of Life, What Is Modified Food Starch Made Of, 2022 Mazda Cx-5 Parts, Replace Conditional With Polymorphism Javascript, Ethical Employer-employee Relationship, Stata Boxplot Outliers, Uwgb Men's Basketball, A Friend Vs My Friend Relationship, Python Split String Into Float,
